Iovance Biotherapeutics is showing promising technical momentum, with a daily gap forming around the ~$2.00 level. A breakout above ~$3.21 would signal the next leg of strength, with the stock poised to target the $4.45 resistance. This setup presents an attractive risk‑to‑reward profile, with a stop‑loss set at $2.78 to manage downside risk.
On the fundamentals side, Iovance is a clinical‑stage biotech firm focusing on tumor‑infiltrating lymphocyte (TIL) therapies for solid tumors.
Their pipeline includes lead candidate lifileucel (AMTAGVI®) in multiple cancer types, highlighting potential for significant upside if trial and regulatory outcomes go well.
Given the technical setup and the biotech growth narrative, I view IOVA as a long‑term hold up to ~$7.11, beyond the near‑term target of $4.45.
IOVA
https://www.tradingview.com/x/UxY14IzB/
On the fundamentals side, Iovance is a clinical‑stage biotech firm focusing on tumor‑infiltrating lymphocyte (TIL) therapies for solid tumors.
Their pipeline includes lead candidate lifileucel (AMTAGVI®) in multiple cancer types, highlighting potential for significant upside if trial and regulatory outcomes go well.
Given the technical setup and the biotech growth narrative, I view IOVA as a long‑term hold up to ~$7.11, beyond the near‑term target of $4.45.
IOVA https://www.tradingview.com/x/UxY14IzB/
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.